Status:
COMPLETED
Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment
Lead Sponsor:
Daiichi Sankyo
Conditions:
Non-small Cell Lung Cancer
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study will use real-world data to assess prevalence of brain metastases in metastatic non-small cell lung cancer (mNSCLC) patients and its impact on associated clinical outcomes.
Detailed Description
This retrospective cohort database study will generate real-world evidence describing prevalence of brain metastases at metastatic diagnosis and by line of therapy, patient characteristics, treatment ...
Eligibility Criteria
Inclusion
- Diagnosis of mNSCLC in study period (01/01/2015-06/30/2023) including newly diagnosed at metastatic stage or progression from advanced stage NSCLC
- Age 18+ years at the time of diagnosis of mNSCLC
- Additional inclusion criteria for 1st Line of Therapy cohort:
- Treated with systemic anti-cancer therapy in 1L setting
- Additional inclusion criteria for 2nd Line of Therapy and 3rd Line of Therapy cohorts:
- Treated with systemic anti-cancer therapy in 2L setting treated with systemic anti-cancer therapy in 3L setting
Exclusion
- Evidence of other primary malignancy in the 365-day baseline period immediately prior to the first mNSCLC diagnosis in the study period
- Evidence of stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT), or whole brain radiotherapy (WBRT) in the baseline period
Key Trial Info
Start Date :
March 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
22517 Patients enrolled
Trial Details
Trial ID
NCT06557967
Start Date
March 1 2024
End Date
September 30 2024
Last Update
December 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ConcertAI Database
Cambridge, Massachusetts, United States, 02138